Sionna Therapeutics (SION) Competitors $12.96 -0.54 (-4.00%) As of 11:00 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock SION vs. ARWR, VCEL, BLTE, APLS, NAMS, AAPG, GMTX, DNLI, HRMY, and KYMRShould you be buying Sionna Therapeutics stock or one of its competitors? The main competitors of Sionna Therapeutics include Arrowhead Pharmaceuticals (ARWR), Vericel (VCEL), Belite Bio (BLTE), Apellis Pharmaceuticals (APLS), NewAmsterdam Pharma (NAMS), Ascentage Pharma Group International (AAPG), Gemini Therapeutics (GMTX), Denali Therapeutics (DNLI), Harmony Biosciences (HRMY), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry. Sionna Therapeutics vs. Arrowhead Pharmaceuticals Vericel Belite Bio Apellis Pharmaceuticals NewAmsterdam Pharma Ascentage Pharma Group International Gemini Therapeutics Denali Therapeutics Harmony Biosciences Kymera Therapeutics Sionna Therapeutics (NASDAQ:SION) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends. Which has preferable earnings and valuation, SION or ARWR? Sionna Therapeutics has higher earnings, but lower revenue than Arrowhead Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSionna TherapeuticsN/AN/AN/AN/AN/AArrowhead Pharmaceuticals$545.21M3.88-$599.49M-$1.40-10.94 Do analysts rate SION or ARWR? Sionna Therapeutics presently has a consensus target price of $38.50, indicating a potential upside of 185.19%. Arrowhead Pharmaceuticals has a consensus target price of $42.13, indicating a potential upside of 175.15%. Given Sionna Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sionna Therapeutics is more favorable than Arrowhead Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sionna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Arrowhead Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the MarketBeat Community favor SION or ARWR? Arrowhead Pharmaceuticals received 548 more outperform votes than Sionna Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Sionna Therapeutics an outperform vote while only 65.44% of users gave Arrowhead Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSionna TherapeuticsOutperform Votes3100.00% Underperform VotesNo VotesArrowhead PharmaceuticalsOutperform Votes55165.44% Underperform Votes29134.56% Do insiders & institutionals have more ownership in SION or ARWR? 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 3.9% of Sionna Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is SION or ARWR more profitable? Sionna Therapeutics' return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Sionna TherapeuticsN/A N/A N/A Arrowhead Pharmaceuticals N/A -236.60%-64.09% Does the media refer more to SION or ARWR? In the previous week, Arrowhead Pharmaceuticals had 32 more articles in the media than Sionna Therapeutics. MarketBeat recorded 34 mentions for Arrowhead Pharmaceuticals and 2 mentions for Sionna Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 0.83 beat Sionna Therapeutics' score of 0.09 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 10 Very Positive mention(s) 6 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryArrowhead Pharmaceuticals beats Sionna Therapeutics on 7 of the 12 factors compared between the two stocks. Get Sionna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SION and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SION vs. The Competition Export to ExcelMetricSionna TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$595.67M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E RatioN/A8.9226.8419.71Price / SalesN/A253.80392.34117.39Price / CashN/A65.8538.2534.62Price / BookN/A6.466.794.50Net IncomeN/A$143.98M$3.23B$248.18M7 Day Performance12.50%3.04%4.07%1.14%1 Month Performance19.47%7.44%12.52%15.20%1 Year PerformanceN/A-2.46%16.83%6.56% Sionna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SIONSionna TherapeuticsN/A$12.98-3.9%$38.50+196.6%N/A$572.73MN/A0.0035ARWRArrowhead Pharmaceuticals3.5175 of 5 stars$15.06+1.0%$42.13+179.7%-38.8%$2.07B$2.50M-2.92400News CoverageAnalyst ForecastAnalyst RevisionVCELVericel2.5572 of 5 stars$41.36-2.2%$60.86+47.1%-20.3%$2.07B$238.54M687.41300News CoveragePositive NewsAnalyst ForecastBLTEBelite Bio2.0577 of 5 stars$64.98+5.5%$96.67+48.8%+48.2%$2.04BN/A-57.8210News CoverageAnalyst RevisionGap UpAPLSApellis Pharmaceuticals4.1775 of 5 stars$16.32-2.3%$40.42+147.7%-59.1%$2.04B$775.84M-8.01770Gap UpNAMSNewAmsterdam Pharma2.6636 of 5 stars$18.59-0.9%$43.00+131.4%-5.0%$2.03B$45.56M-9.814Positive NewsAAPGAscentage Pharma Group InternationalN/A$23.25-0.6%N/AN/A$2.02B$980.65M0.00600Positive NewsGap UpGMTXGemini TherapeuticsN/A$46.35-0.6%N/A+54.7%$2.01BN/A-46.3530DNLIDenali Therapeutics4.42 of 5 stars$13.79-1.3%$33.79+145.1%-31.5%$2.00B$330.53M-4.98430Analyst ForecastGap UpHRMYHarmony Biosciences4.7847 of 5 stars$33.91+1.6%$52.33+54.3%+16.4%$1.95B$744.85M16.05200Positive NewsKYMRKymera Therapeutics2.7085 of 5 stars$29.64-0.4%$55.27+86.5%-14.7%$1.93B$58.89M-12.65170Analyst ForecastGap Down Related Companies and Tools Related Companies ARWR Alternatives VCEL Alternatives BLTE Alternatives APLS Alternatives NAMS Alternatives AAPG Alternatives GMTX Alternatives DNLI Alternatives HRMY Alternatives KYMR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SION) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sionna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sionna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
